Literature DB >> 15980012

Normal gestations and live births after orthotopic autograft of vitrified-warmed hemi-ovaries into ewes.

Agnes Bordes1, Jacqueline Lornage, Banu Demirci, Michel Franck, Blandine Courbiere, Jean François Guerin, Bruno Salle.   

Abstract

BACKGROUND: The aim of this study was to evaluate the long-term outcome of autotransplantation of vitrified warmed hemi-ovaries into ewes.
METHODS: Six hemi-ovaries from six ewes aged 6 to 12 months were vitrified. After dissection of the medulla, the hemi-ovarian cortex was stored at -196 degrees C in liquid nitrogen. Four to six weeks after the first laparotomy, the left ovary was removed and the vitrified-warmed hemi-ovary was sutured.
RESULTS: Plasma progesterone concentration increased in a regular manner in all ewes. Three pregnancies occurred, from which four lambs were born. The first delivery of a normal lamb occurred in February 2003. The second delivery of two normal lambs occurred in March 2003 (a 2.5 kg male and a 2.8 kg female). The last lamb had a normal delivery but had a malformation of the left leg and the oesophagus. This lamb died two months after delivery from pneumariae. Histological examination of the grafted vitrified ovaries showed few primordial and antral follicles.
CONCLUSIONS: These three pregnancies in a ewe model may indicate that ovarian vitrification gives results as good as those from a slow cooling protocol in autograft. It is impossible to establish a link between the vitrification procedure and the malformation of the last lamb, and further studies are needed to evaluate the feasibility of ovarian vitrification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980012     DOI: 10.1093/humrep/dei155

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  9 in total

Review 1.  Recent advances in oocyte and ovarian tissue cryopreservation and transplantation.

Authors:  Kenny A Rodriguez-Wallberg; Kutluk Oktay
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-01       Impact factor: 5.237

Review 2.  Fertility preservation through gonadal cryopreservation.

Authors:  Lalitha Devi; Sandeep Goel
Journal:  Reprod Med Biol       Date:  2016-03-11

3.  Heterotopic autotransplantation of vitrified mouse ovary.

Authors:  Hussein Eimani; Arash Behbahanian; Bahman Zeinali; Mojtaba Rezazade Valoujerdi; Poopak Eftekhari; Abdulhussein Shahverdi; Hamid Gourabi; Afsaneh Golkar-Narenji
Journal:  Reprod Med Biol       Date:  2011-10-05

4.  Fertility preservation for women with malignancies: current developments of cryopreservation.

Authors:  Hye Jin Chang; Chang Suk Suh
Journal:  J Gynecol Oncol       Date:  2008-06-20       Impact factor: 4.401

5.  Morphology and function of cryopreserved whole ovine ovaries after heterotopic autotransplantation.

Authors:  Anna T Grazul-Bilska; Jashoman Banerjee; Ilker Yazici; Ewa Borowczyk; Jerzy J Bilski; Rakesh K Sharma; Maria Siemionov; Tommaso Falcone
Journal:  Reprod Biol Endocrinol       Date:  2008-04-11       Impact factor: 5.211

6.  Vitrification of human ovarian tissue: a practical and relevant alternative to slow freezing.

Authors:  Sandra Sanfilippo; Michel Canis; Johan Smitz; Benoît Sion; Claude Darcha; Laurent Janny; Florence Brugnon
Journal:  Reprod Biol Endocrinol       Date:  2015-06-25       Impact factor: 5.211

Review 7.  Orthotopic and heterotopic ovarian tissue transplantation.

Authors:  I Demeestere; P Simon; S Emiliani; A Delbaere; Y Englert
Journal:  Hum Reprod Update       Date:  2009-05-27       Impact factor: 15.610

8.  Preservation of female fertility in humans and animal species.

Authors:  Helen Mary Picton
Journal:  Anim Reprod       Date:  2018-08-17       Impact factor: 1.807

9.  Good preservation of stromal cells and no apoptosis in human ovarian tissue after vitrification.

Authors:  Raffaella Fabbri; Rossella Vicenti; Maria Macciocca; Gianandrea Pasquinelli; Roberto Paradisi; Cesare Battaglia; Nicola Antonio Martino; Stefano Venturoli
Journal:  Biomed Res Int       Date:  2014-04-03       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.